Viewed: 711
Emailed: 0
PDF Downloaded: 823
Full Text PDF Share on Facebook Share on Twitter
Original Article
Author Details :
Volume : 11, Issue : 3, Year : 2021
Article Page : 491-493
https://10.18231/j.pjms.2021.095
Abstract
Corona virus disease is a most contagious disease caused by a newly discovered corona virus, initially identified in the Mainland of China(Wuhan) in late December 2019. Covid-19 has been initiated as a highly infectious disease that can spread quickly in a community population depending the number of susceptible and infected larger number of cases and also depending on their movement in the community.This study was conducted from September to November 2020 in PRM Medical College and Hospital Baripada, Mayurbhanj, Odisha, in COVID 19 isolation ward. This study is approved by IEC, PRM MCH
Baripada.
Covid -19 pt is more male preponderant due to community movement and the incidence in more at the age of 40-50 yrs. It was seen that 20% prescription contain more than 10 drugs although it is a polypharmacy and increase cost to the pt as well as to govt. It may increase ADR. About 20 % pt are in comorbid condition and also they required parental preparation, oxygen inhalation. Only 10% pt required antiviral drugs such as Favipiravir depending on the symptoms and viral load. All the drug supplied from Govt hospital store except very few which was not available in the hospital. All are prescribed in generic name and from essential drug list except very few.Drug utilisation pattern may improve the rational use of drugs, reduce cost, polypharmacy and ADR.
Keywords: COVID-19, Favipiravir
How to cite : Tarai A, Beshra S, Pattnaik K P, Misra K H, Giri S, Study of drug utilisation pattern of COVID- 19 positive cases in isolation ward of PRM Medical College and Hospital, Baripada, Mayurbhanj, Odisha. Panacea J Med Sci 2021;11(3):491-493
Copyright © 2021 by author(s) and Panacea J Med Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)